BiomX (NYSEAMERICAN:PHGE) Shares Down 2.7% – Here’s What Happened

BiomX Inc. (NYSEAMERICAN:PHGE)’s share price fell 2.7% during trading on Wednesday . The company traded as low as $2.85 and last traded at $2.90. 58,984 shares traded hands during mid-day trading, a decline of 33% from the average session volume of 88,382 shares. The stock had previously closed at $2.98.

Analysts Set New Price Targets

Separately, HC Wainwright lowered BiomX from a “buy” rating to a “hold” rating in a research note on Monday, March 9th. One research analyst has rated the stock with a Hold rating, Based on data from MarketBeat, BiomX currently has a consensus rating of “Hold” and an average price target of $26.00.

BiomX Price Performance

The stock has a 50 day moving average price of $5.14 and a 200-day moving average price of $5.77. The stock has a market capitalization of $4.61 million, a price-to-earnings ratio of -0.11 and a beta of 1.69.

BiomX (NYSEAMERICAN:PHGE) last issued its quarterly earnings results on Thursday, February 19th. The company reported $6.99 earnings per share (EPS) for the quarter. As a group, research analysts forecast that BiomX Inc. will post -2.77 earnings per share for the current year.

Insiders Place Their Bets

In other BiomX news, Director Reuven Yeganeh sold 530,000 shares of the business’s stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $5.00, for a total transaction of $2,650,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 21.80% of the company’s stock.

Hedge Funds Weigh In On BiomX

A hedge fund recently bought a new stake in BiomX stock. Citadel Advisors LLC acquired a new position in shares of BiomX Inc. (NYSEAMERICAN:PHGE) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 161,781 shares of the company’s stock, valued at approximately $85,000. Citadel Advisors LLC owned about 0.61% of BiomX as of its most recent filing with the Securities and Exchange Commission (SEC). 40.57% of the stock is owned by institutional investors.

About BiomX

BiomX Inc is a clinical-stage biotechnology company that specializes in developing precision bacteriophage therapies to target pathogenic bacteria in the human microbiome. By harnessing the natural ability of bacteriophages to selectively infect and lyse harmful bacterial strains, BiomX aims to restore microbial balance without disrupting beneficial commensal organisms. The company’s platform integrates phage discovery, formulation and genetic engineering to create tailored phage cocktails for a range of microbiome-associated diseases.

The company’s pipeline includes lead clinical candidates for gastrointestinal disorders such as pouchitis and ulcerative colitis, as well as programs addressing dermatological indications including acne and atopic dermatitis.